Collection: Drinkware
Sip with impact from our Drinkware collection, where style meets support. Featuring a variety of high-quality wine tumblers, insulated cups, and more, this collection is crafted to keep your beverages at the perfect temperature—whether you’re enjoying a cozy hot drink or a chilled refreshment. Each piece is designed for durability and convenience, making it a go-to for home, work, or on-the-go adventures.
More than just drinkware, every item in this collection helps fund pancreatic cancer research. Profits from this collection go to Sky Foundation, a non-profit that funds pancreatic cancer research. With every sip, you’re helping to support a meaningful cause.
Choose a piece from our collection and raise a glass to making a difference.

-
Tumbler 20oz (Purple Bokeh)
Regular price $26.65 USDRegular priceUnit price / per -
Tumbler 20oz (Purple Butterfly)
Regular price $26.65 USDRegular priceUnit price / per -
Tumbler 20oz (Purple Dark)
Regular price $26.65 USDRegular priceUnit price / per -
Tumbler 20oz (Purple Fancy)
Regular price $26.65 USDRegular priceUnit price / per -
Tumbler 20oz (Purple Field)
Regular price $26.65 USDRegular priceUnit price / per -
Tumbler 20oz (Purple Floral)
Regular price $26.65 USDRegular priceUnit price / per -
Tumbler 20oz (Purple Gradient)
Regular price $26.65 USDRegular priceUnit price / per -
Tumbler 20oz (Purple Jewels)
Regular price $26.65 USDRegular priceUnit price / per -
Tumbler 20oz (Purple Light)
Regular price $26.65 USDRegular priceUnit price / per -
Tumbler 20oz (Purple Lux)
Regular price $26.65 USDRegular priceUnit price / per -
Tumbler 20oz (Purple Marble)
Regular price $26.65 USDRegular priceUnit price / per -
Tumbler 20oz (Purple Medium)
Regular price $26.65 USDRegular priceUnit price / per -
Tumbler 20oz (Purple Sky)
Regular price $26.65 USDRegular priceUnit price / per -
Tumbler 20oz (Purple Tiger)
Regular price $26.65 USDRegular priceUnit price / per
Latest News
View all-
Phase 1/2 Trial Launches for Innovative Pancrea...
UCSF researchers begin testing novel TCR-T cell therapy targeting KRAS mutations in advanced pancreatic cancer. A new clinical trial at UCSF has opened to test a first-of-its-kind immunotherapy for advanced...
Phase 1/2 Trial Launches for Innovative Pancrea...
UCSF researchers begin testing novel TCR-T cell therapy targeting KRAS mutations in advanced pancreatic cancer. A new clinical trial at UCSF has opened to test a first-of-its-kind immunotherapy for advanced...
-
FDA Approves NALIRIFOX as First-Line Treatment ...
New frontline treatment offers hope with improved survival outcomes for advanced PDAC patients The U.S. Food and Drug Administration (FDA) has officially approved NALIRIFOX, a new frontline therapy for patients with metastatic...
FDA Approves NALIRIFOX as First-Line Treatment ...
New frontline treatment offers hope with improved survival outcomes for advanced PDAC patients The U.S. Food and Drug Administration (FDA) has officially approved NALIRIFOX, a new frontline therapy for patients with metastatic...
-
Immunotherapy for Pancreatic Ductal Adenocarcin...
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers, with a 5-year survival rate under 10%. Standard treatments like surgery and chemotherapy often fail because the cancer usually comes...
Immunotherapy for Pancreatic Ductal Adenocarcin...
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers, with a 5-year survival rate under 10%. Standard treatments like surgery and chemotherapy often fail because the cancer usually comes...